Pew Calls on Congress to Support Telehealth for Addiction Treatment

TREATS Act would improve access to lifesaving medication for opioid use disorder

Congress Should Support Telehealth Treatment for Addiction

On Feb. 15, The Pew Charitable Trusts, the National Rural Health Association, and Faces and Voices of Recovery wrote to congressional leadership urging swift passage of the Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act (H.R. 5163/S. 3193). Nearly 130 organizations, including the American Society of Addiction Medicine and the National Safety Council, have signed on in support.

The TREATS Act would permanently allow patients with opioid use disorder to be evaluated and begin treatment with buprenorphine—an FDA-approved medication proved to reduce overdose risk and promote recovery—remotely, through either an audio-video or audio-only appointment. Temporary regulations put in place during the COVID-19 pandemic have allowed more patients to access buprenorphine than ever via telehealth, but these rules are set to expire at the end of 2024, forcing patients to return to in-person care unless Congress acts.

Pew’s letter asks Congress to pass the TREATS Act to preserve this critical lifeline to treatment.

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.